Inogen, Inc to Post Q3 2017 Earnings of $0.33 Per Share, William Blair Forecasts (INGN)
Inogen, Inc (NASDAQ:INGN) – Equities research analysts at William Blair boosted their Q3 2017 earnings estimates for shares of Inogen in a research report issued on Thursday. William Blair analyst M. Kaczor now anticipates that the medical technology company will post earnings of $0.33 per share for the quarter, up from their previous forecast of $0.30. William Blair also issued estimates for Inogen’s FY2017 earnings at $1.23 EPS, Q1 2018 earnings at $0.24 EPS, Q3 2018 earnings at $0.40 EPS, Q4 2018 earnings at $0.33 EPS and FY2018 earnings at $1.39 EPS.
Inogen (NASDAQ:INGN) last issued its quarterly earnings results on Thursday, August 3rd. The medical technology company reported $0.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.10. Inogen had a net margin of 10.36% and a return on equity of 12.45%. The firm had revenue of $64.10 million for the quarter, compared to analyst estimates of $59.99 million. During the same period in the previous year, the business earned $0.25 EPS. The company’s revenue was up 17.4% compared to the same quarter last year. WARNING: “Inogen, Inc to Post Q3 2017 Earnings of $0.33 Per Share, William Blair Forecasts (INGN)” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.thecerbatgem.com/2017/08/19/inogen-inc-to-post-q3-2017-earnings-of-0-33-per-share-william-blair-forecasts-ingn-updated.html.
Other research analysts also recently issued research reports about the stock. BidaskClub upgraded shares of Inogen from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Zacks Investment Research downgraded shares of Inogen from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Needham & Company LLC upped their price objective on shares of Inogen from $96.00 to $108.00 and gave the stock a “strong-buy” rating in a report on Friday, June 9th. Stifel Nicolaus upped their price objective on shares of Inogen from $65.00 to $75.00 and gave the stock a “hold” rating in a report on Wednesday, May 10th. Finally, Sidoti began coverage on shares of Inogen in a report on Tuesday, April 18th. They set a “neutral” rating and a $79.00 price objective on the stock. Three research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $91.60.
Shares of Inogen (INGN) opened at 92.76 on Monday. The firm has a 50-day moving average of $94.81 and a 200 day moving average of $81.21. The firm has a market capitalization of $1.91 billion, a price-to-earnings ratio of 82.97 and a beta of 1.01. Inogen has a 52 week low of $50.24 and a 52 week high of $98.33.
Several hedge funds have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. purchased a new stake in shares of Inogen during the first quarter valued at approximately $109,000. Victory Capital Management Inc. increased its stake in shares of Inogen by 36.1% in the first quarter. Victory Capital Management Inc. now owns 1,729 shares of the medical technology company’s stock valued at $134,000 after buying an additional 459 shares in the last quarter. State of Alaska Department of Revenue increased its stake in shares of Inogen by 4.1% in the first quarter. State of Alaska Department of Revenue now owns 1,790 shares of the medical technology company’s stock valued at $138,000 after buying an additional 70 shares in the last quarter. Sei Investments Co. increased its stake in shares of Inogen by 38.1% in the second quarter. Sei Investments Co. now owns 1,606 shares of the medical technology company’s stock valued at $153,000 after buying an additional 443 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of Inogen during the first quarter valued at approximately $203,000.
In other news, Director Ray Benjamin M. Anderson sold 4,445 shares of the stock in a transaction dated Thursday, May 18th. The shares were sold at an average price of $81.05, for a total value of $360,267.25. Following the completion of the sale, the director now owns 4,445 shares in the company, valued at $360,267.25. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Heath Lukatch sold 9,000 shares of the stock in a transaction dated Tuesday, May 30th. The shares were sold at an average price of $88.52, for a total transaction of $796,680.00. Following the completion of the sale, the director now owns 7,246 shares of the company’s stock, valued at approximately $641,415.92. The disclosure for this sale can be found here. In the last quarter, insiders sold 81,182 shares of company stock valued at $7,277,088. 5.31% of the stock is currently owned by corporate insiders.
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Stock Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related stocks with our FREE daily email newsletter.